ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
Ticker SymbolICCC
Company nameImmuCell Corp
IPO dateMay 01, 1987
CEOMr. Michael F. Brigham
Number of employees69
Security typeOrdinary Share
Fiscal year-endMay 01
Address56 Evergreen Drive
CityPORTLAND
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code04103
Phone12078782770
Websitehttps://immucell.com/
Ticker SymbolICCC
IPO dateMay 01, 1987
CEOMr. Michael F. Brigham
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data